A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

Completed

• Conditions: Liver Diseases
• Interventions: Drug: Dasatinib

• Registration Number: NCT00382668
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-09-26
• Study First Submitted QC: 2006-09-28
• Study First Posted: 2006-09-29
• Study Start: 2006-10
• Primary Completion: 2007-08
• Study Completion: 2007-08
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-13
• Last Update Posted: 2011-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
A	Dasatinib	-
B	Dasatinib	-
C	Dasatinib	-

Trial Locations

Locations (4)

University Of Miami; 🇺🇸 Miami, Florida, United States

New Orleans Center For Clinical Research; 🇺🇸 Knoxville, Tennessee, United States

Comprehensive Phase One; 🇺🇸 Miramar, Florida, United States

Orlando Clinical Research Center; 🇺🇸 Orlando, Florida, United States